Imbruvica achieves 67% ORR in chronic graft-versus-host-disease

Janssen Research and Development, a subsidiary of the US health care giant Johnson & Johnson (NYSE: JNJ), has presented Phase II data on Imbruvica (ibrutinib) in chronic graft-versus-host-disease (cGVHD), who failed prior systemic therapy.

The findings, presented at the 58th American Society of Hematology (ASH) Annual Meeting, show that ibrutinib demonstrated clinically meaningful and durable responses and reduced symptom severity, with an overall response rate (ORR) of 67% in patients with this life-threatening consequence of stem cell or bone marrow transplant.

"We look forward to further exploring the potential of ibrutinib as initial therapy for this serious condition with the initiation of a Phase III trial in the first-line setting"